Literature DB >> 1610985

Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome.

A Schieppati1, P Ruggenenti, R P Cornejo, F Ferrario, G Gregorini, P Zucchelli, E Rossi, G Remuzzi.   

Abstract

The clinical records of adult patients with a diagnosis of hemolytic uremic syndrome were retrospectively reviewed with the aim of evaluating the long-term outcome of renal function. The setting is the Italian Registry of Haemolytic Uraemic Syndrome, with which 13 Nephrology Centers have participated. Clinical and laboratory data of 43 patients with hemolytic uremic syndrome were evaluated. The mean age at onset was 34.3 +/- 18.3 yr. Men and women were equally affected. No seasonal trend in presentation was observed. In 20 patients, hemolytic uremic syndrome was primitive, whereas in 23, it was associated with another disease (cancer, preeclampsia, malignant hypertension, vasculitides). Gastrointestinal symptoms were the most frequently observed prodromes. Thirty (70%) patients required dialysis during the acute phase of the disease. Six patients died during the acute phase of the disease, and one died later after discharge (overall mortality, 16%). After 1 yr of follow-up, 11 (26%) patients had recovered a normal renal function, 14 (33%) had hypertension and/or renal insufficiency, and 11 (26%) were on regular dialysis. When prognostic factors of survival and recovery of renal function were considered, it was found that older age was associated with higher mortality in the acute phase, whereas severe renal involvement at the onset of the disease (as expressed by elevated serum creatinine) was associated with a long-term unfavorable prognosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1610985     DOI: 10.1681/ASN.V2111640

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  17 in total

1.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 2.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

3.  Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome.

Authors:  Gianluigi Ardissino; Valeria Daccò; Sara Testa; Cristina Felice Civitillo; Francesca Tel; Ilaria Possenti; Mirco Belingheri; Pierangela Castorina; Nicolò Bolsa-Ghiringhelli; Silvana Tedeschi; Fabio Paglialonga; Stefania Salardi; Dario Consonni; Elena Zoia; Patrizia Salice; Giovanna Chidini
Journal:  Pediatr Nephrol       Date:  2014-08-23       Impact factor: 3.714

4.  Hemolytic uremic syndrome after renal transplantation.

Authors:  G V Vergoulas
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

Review 5.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

Review 6.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

Review 7.  Pathogenesis and prognosis of thrombotic microangiopathy.

Authors:  Masaomi Nangaku; Hiroshi Nishi; Toshiro Fujita
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

Review 8.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

9.  Indicators of acute and persistent renal damage in adult thrombotic microangiopathy.

Authors:  Firuseh Dierkes; Nikolaos Andriopoulos; Christoph Sucker; Kathrin Kuhr; Markus Hollenbeck; Gerd R Hetzel; Volker Burst; Sven Teschner; Lars C Rump; Thomas Benzing; Bernd Grabensee; Christine E Kurschat
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

10.  Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria.

Authors:  Sacha A De Serres; Paul Isenring
Journal:  Nephrol Dial Transplant       Date:  2008-12-18       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.